Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Mixed Results With TMB as NSCLC Marker

Key clinical point: Tumor mutational burden (TMB) needs further refinement as a marker for non-small cell lung cancer (NSCLC).

Major finding: High TMB was significantly more frequent in metastases than primary tumors.

Study details: Analysis of samples from 3,424 patients with NSCLC.

Disclosures: The investigators did not report a study funding source. Dr. Stein reported no relevant disclosures. Several of the coauthors are employees of Caris Life Sciences, which performed the tumor profiling.

Citation:

Stein MK et al. JCO Precision Oncology. 2019 Jul 26. doi: 10.1200/PO.18.00376.